Post-Marketing Safety Surveillance Should Include Data Mining Techniques, FDA Says

The advantages and limitations of data analysis from large adverse event databases are described in a draft guidance. Safety signals found through data mining should be put in the context of total patients exposed to the drug and considered for further investigation, FDA recommends.